Skip to main content
Industry News
Rare pediatric disease tag granted for GM1 gangliosidosis gene therapy
5/22/2020

Passage Bio's gene therapy candidate PBGM01 was granted rare pediatric disease designation by the FDA as a treatment of infantile GM1 gangliosidosis. Passage BIO plans to launch a Phase I/II clinical trial in the fourth quarter for PBGM0.

Full Story: